Xenon Pharmaceuticals Inc.
XENE
$34.70
-$0.41-1.17%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -65.69M | -62.79M | -57.92M | -47.93M | -44.74M |
| Total Depreciation and Amortization | 633.00K | 669.00K | 659.00K | 599.00K | -629.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 8.48M | 11.89M | 14.50M | 9.81M | 10.23M |
| Change in Net Operating Assets | 2.19M | -911.00K | 10.09M | -5.65M | -255.00K |
| Cash from Operations | -54.39M | -51.15M | -32.68M | -43.18M | -35.40M |
| Capital Expenditure | -783.00K | -590.00K | -1.51M | -188.00K | -78.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 99.29M | 2.57M | 112.23M | -46.01M | -239.71M |
| Cash from Investing | 98.50M | 1.98M | 110.72M | -46.20M | -239.79M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 12.13M | -- | -- | -- | 324.01M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 12.13M | -- | -- | -- | 324.01M |
| Foreign Exchange rate Adjustments | -1.16M | 54.00K | -202.00K | -367.00K | 246.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 55.09M | -49.11M | 77.84M | -89.75M | 49.07M |